The COVID-19 pandemic is a wake-up call for the pharmaceutical industry to embed digital transformation at every level of its operations. That includes market access, tendering and pharma product launch activities.
0 Comments Click here to read/write comments
Topics: launch planning, #covid-19, digital transformation
While some errors are unforeseen, many can be prevented with better planning, coordination, communication and transparency in launch planning and implementation. In our article for PME, we make the case for why pharma companies need a launch execution platform that makes launch excellence the norm, builds the corporate launch memory, and streamlines efforts to save time for everyone involved in product launches.
The importance of a pharma product’s launch to its success cannot be overstated. A recent analysis by Deloitte showed that most new drugs continue with the revenue trajectory set at launch – around 70 percent of products that miss expectations at launch continue doing so in subsequent years, and around 80 percent of products that meet or beat expectations continue to do so afterward.
0 Comments Click here to read/write comments
Topics: launch excellence, launch execution, product launches
It is probably reasonable enough by now to talk about the launch readiness landscape for medicines and vaccines as pre- and post-COVID. We can also say with some certainty that nothing will ever be the same again.
0 Comments Click here to read/write comments
Topics: launch readiness, launch strategy, launch effectiveness, launch readiness framework, launch plan, pharma tenders
The COVID-19 pandemic has eclipsed every other development in healthcare and pharmaceuticals during 2020. It will likely do so next year as well. Looking ahead to 5 pharma trends for 2021 that will set the agenda for industry, it is hard to escape COVID-19 both as a challenge and a spur to new directions.
0 Comments Click here to read/write comments
Topics: Pharma trends, launch trends, launch readiness, AI
Any fears that COVID-19 might stem the flow of new drug approvals in 2020, depleting or diverting resources at regulatory agencies and their pharmaceutical clients, appear largely premature.
0 Comments Click here to read/write comments
Topics: Pharma launch planning, launch readiness, EMA Approvals, FDA Approvals
